Clinical factors such as tumor size, tumor grade, lymph node status, age, and the immunochemical status of the three tumor receptors—estrogen receptor (ER), progesterone receptor (PR), and HER2—are taken into consideration while deciding on adjuvant therapy. Here, PGR is linked to neoplasm.